The multinational has filed infringement proceedings and is seeking an injunction against the Indian rival at the Delhi High Court, trying to block the Bangalore-based biotechnology firm from launching a generic version of Galvus, also known as vildagliptin.
According to industry estimates, Galvus, one of the best-selling medicines of Novartis, clocks Rs 200 crore (Rs 2 billion) of sales annually.
Besides, Novartis also has a co-marketing tie-up with USV to sell the drug at a lower price under a different brand name, Jalra, in Tier-II and -III cities.
A Novartis spokesperson said: “During the hearing (at the high court) on March 28,
Big Pharma still betting on 'messed up' Indian drugs market
India must call the US' bluff on patents
Big Pharma still betting on 'messed up' Indian drugs market
Consumers may have to pay more for insulin
Gay sex: SC agrees to consider curative petition in open court